100 related articles for article (PubMed ID: 27466538)
1. Improved Efficacy by Addition of Protein-bound Polysaccharide K to Adjuvant Chemotherapy for Advanced Gastric Cancer.
Fukuchi M; Mochiki E; Ishiguro T; Ogura T; Sobajima J; Kumagai Y; Ishibashi K; Ishida H
Anticancer Res; 2016 Aug; 36(8):4237-41. PubMed ID: 27466538
[TBL] [Abstract][Full Text] [Related]
2. Clinical efficacy of protein-bound polysaccharide K in patients with gastric cancer undergoing chemotherapy with an oral fluoropyrimidine (S-1).
Namikawa T; Fukudome I; Ogawa M; Munekage E; Munekage M; Shiga M; Maeda H; Kitagawa H; Kobayashi M; Hanazaki K
Eur J Surg Oncol; 2015 Jun; 41(6):795-800. PubMed ID: 25887287
[TBL] [Abstract][Full Text] [Related]
3. PSK may suppress CD57(+) T cells to improve survival of advanced gastric cancer patients.
Akagi J; Baba H
Int J Clin Oncol; 2010 Apr; 15(2):145-52. PubMed ID: 20229169
[TBL] [Abstract][Full Text] [Related]
4. [The Clinical Role of the Neutrophil/Lymphocyte Ratio in Patients with Advanced Gastric Cancer Treated with Protein-Bound Polysaccharide K and Chemotherapy].
Namikawa T; Munekage E; Munekage M; Shiga M; Maeda H; Kitagawa H; Okamoto K; Kumon M; Kobayashi M; Hanazaki K
Gan To Kagaku Ryoho; 2015 Nov; 42(12):2081-3. PubMed ID: 26805271
[TBL] [Abstract][Full Text] [Related]
5. A randomized phase III trial of postoperative adjuvant therapy with S-1 alone versus S-1 plus PSK for stage II/IIIA gastric cancer: Hokuriku-Kinki Immunochemo-Therapy Study Group-Gastric Cancer (HKIT-GC).
Ueda Y; Fujimura T; Kinami S; Hirono Y; Yamaguchi A; Naitoh H; Tani T; Kaji M; Yamagishi H; Miwa K;
Jpn J Clin Oncol; 2006 Aug; 36(8):519-22. PubMed ID: 16803844
[TBL] [Abstract][Full Text] [Related]
6. Comparison of capecitabine and oxaliplatin with S-1 as adjuvant chemotherapy in stage III gastric cancer after D2 gastrectomy.
Cho JH; Lim JY; Cho JY
PLoS One; 2017; 12(10):e0186362. PubMed ID: 29040299
[TBL] [Abstract][Full Text] [Related]
7. Sequential paclitaxel followed by tegafur and uracil (UFT) or S-1 versus UFT or S-1 monotherapy as adjuvant chemotherapy for T4a/b gastric cancer (SAMIT): a phase 3 factorial randomised controlled trial.
Tsuburaya A; Yoshida K; Kobayashi M; Yoshino S; Takahashi M; Takiguchi N; Tanabe K; Takahashi N; Imamura H; Tatsumoto N; Hara A; Nishikawa K; Fukushima R; Nozaki I; Kojima H; Miyashita Y; Oba K; Buyse M; Morita S; Sakamoto J
Lancet Oncol; 2014 Jul; 15(8):886-93. PubMed ID: 24954805
[TBL] [Abstract][Full Text] [Related]
8. [Current status of adjuvant chemotherapy in patients with p-Stage II and p-Stage III gastric cancer].
Sato Y; Yajima K; Kosugi S; Muneoka Y; Ichikawa H; Hanyu T; Sakamoto K; Ishikawa T; Wakai T
Gan To Kagaku Ryoho; 2014 Aug; 41(8):961-4. PubMed ID: 25132026
[TBL] [Abstract][Full Text] [Related]
9. A phase II study of neoadjuvant chemotherapy with S-1 and cisplatin for stage III gastric cancer: KUGC03.
Okabe H; Hata H; Ueda S; Zaima M; Tokuka A; Yoshimura T; Ota S; Kinjo Y; Yoshimura K; Sakai Y;
J Surg Oncol; 2016 Jan; 113(1):36-41. PubMed ID: 26604064
[TBL] [Abstract][Full Text] [Related]
10. A phase II study of adjuvant S-1/cisplatin chemotherapy followed by S-1-based chemoradiotherapy for D2-resected gastric cancer.
Shim HJ; Kim KR; Hwang JE; Bae WK; Ryu SY; Park YK; Nam TK; Chung IJ; Cho SH
Cancer Chemother Pharmacol; 2016 Mar; 77(3):605-12. PubMed ID: 26846507
[TBL] [Abstract][Full Text] [Related]
11. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer.
Sasako M; Sakuramoto S; Katai H; Kinoshita T; Furukawa H; Yamaguchi T; Nashimoto A; Fujii M; Nakajima T; Ohashi Y
J Clin Oncol; 2011 Nov; 29(33):4387-93. PubMed ID: 22010012
[TBL] [Abstract][Full Text] [Related]
12. An increase in the neutrophil-to-lymphocyte ratio during adjuvant chemotherapy indicates a poor prognosis in patients with stage II or III gastric cancer.
Mori M; Shuto K; Kosugi C; Narushima K; Hayashi H; Matsubara H; Koda K
BMC Cancer; 2018 Dec; 18(1):1261. PubMed ID: 30558575
[TBL] [Abstract][Full Text] [Related]
13. Feasibility study of adjuvant chemotherapy with S-1 plus cisplatin for gastric cancer.
Takahari D; Hamaguchi T; Yoshimura K; Katai H; Ito S; Fuse N; Kinoshita T; Yasui H; Terashima M; Goto M; Tanigawa N; Shirao K; Sano T; Sasako M
Cancer Chemother Pharmacol; 2011 Jun; 67(6):1423-8. PubMed ID: 20809123
[TBL] [Abstract][Full Text] [Related]
14. Phase II feasibility study of adjuvant S-1 plus docetaxel for stage III gastric cancer patients after curative D2 gastrectomy.
Tamura S; Fujitani K; Kimura Y; Tsuji T; Matsuyama J; Iijima S; Imamura H; Inoue K; Kobayashi K; Kurokawa Y; Furukawa H;
Oncology; 2011; 80(5-6):296-300. PubMed ID: 21778769
[TBL] [Abstract][Full Text] [Related]
15. Short-term curative effect of S-1 plus oxaliplatin as perioperative chemotherapy for locally advanced gastric cancer: a prospective comparison study.
Zhao Q; Li Y; Huang J; Fan L; Tan B; Tian Y; Yang P; Jiao Z; Zhao X; Zhang Z; Wang D; Liu Y
Pharmazie; 2017 Apr; 72(4):236-240. PubMed ID: 29441995
[TBL] [Abstract][Full Text] [Related]
16. The effect of polysaccharide k with S-1 based chemotherapy in advanced gastric cancer.
Yoshikawa K; Shimada M; Kurita N; Sato H; Iwata T; Nishioka M; Morimoto S; Miyatani T; Komatsu M; And RN
Hepatogastroenterology; 2013 Sep; 60(126):1387-90. PubMed ID: 23933930
[TBL] [Abstract][Full Text] [Related]
17. A phase II study of docetaxel and oxaliplatin combination in recurrent gastric cancer patients after fluoropyrimidine and/or cisplatin adjuvant treatment: a Korean Cancer Study Group Protocol ST06-02.
Choi YH; Oh SC; Kim JS; Nam SH; Kim BS; Cho SH; Chung IJ; Song EK; Yim CY; Baek JH; Jeung HC; Hong YS; Yang SH; Kang HJ
Cancer Chemother Pharmacol; 2012 Nov; 70(5):665-72. PubMed ID: 22926638
[TBL] [Abstract][Full Text] [Related]
18. High gamma-glutamyl hydrolase and low folylpolyglutamate synthetase expression as prognostic biomarkers in patients with locally advanced gastric cancer who were administrated postoperative adjuvant chemotherapy with S-1.
Maezawa Y; Sakamaki K; Oue N; Kimura Y; Hashimoto I; Hara K; Kano K; Aoyama T; Hiroshima Y; Yamada T; Yamamoto N; Ogata T; Ito H; Cho H; Shiozawa M; Yoshikawa T; Morinaga S; Rino Y; Yasui W; Masuda M; Miyagi Y; Oshima T
J Cancer Res Clin Oncol; 2020 Jan; 146(1):75-86. PubMed ID: 31754833
[TBL] [Abstract][Full Text] [Related]
19. [The future of loco-regional treatment for advanced gastric cancer].
Nagahama T; Ando M; Ganno H; Ami K; Fukuda A; Maruyama M
Gan To Kagaku Ryoho; 2008 Nov; 35(12):2012-4. PubMed ID: 19106507
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of Conversion Surgery Following S-1 plus Cisplatin or Oxaliplatin Chemotherapy for Unresectable Gastric Cancer.
Fukuchi M; Mochiki E; Ishiguro T; Ogura T; Sobajima J; Kumagai Y; Ishibashi K; Ishida H
Anticancer Res; 2017 Mar; 37(3):1343-1347. PubMed ID: 28314301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
